(Total Views: 451)
Posted On: 02/22/2021 11:41:44 AM
Post# of 72440
10Q great news: " In January 2021, Alfasigma notified the Company that the Phase 1 study for the treatment of UP/UPS using Brilacidin in a proprietary Alfasigma formulation was successfully completed. Planning for a Phase 2 clinical trial is underway. The Company is eligible to receive $24 million in upfront and milestone payments, and a 6 percent royalty (net sales) upon the successful marketing of Brilacidin for UP/UPS. "
(10)
(0)
Scroll down for more posts ▼